|
Colorectal Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
Based on the result that SRSF6 RRM2 domain plays key roles in regulating AS and biological function, indacaterol, a β2-adrenergic receptor agonist approved for chronic obstructive pulmonary disease treatment, is identified as the inhibitor of SRSF6 to suppress CRC tumourigenicity.
|
29114070 |
2019 |
|
Colorectal Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
Our results indicate CREB1 as a critical transcription factor of RRM2 which promotes tumor aggressiveness, and imply a significant correlation between CREB1 and RRM2 in CRC specimens.
|
27801665 |
2016 |
|
Colorectal Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
RRM2 represents a novel therapeutic target, thus highlighting the potential utility of RRM2 inhibitors in colorectal cancer with oncogenic KRAS.
|
21873171 |
2011 |
|
Colorectal Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer.
|
21415168 |
2011 |
|
Colorectal Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
This strategy identified the signaling pathways that are affected by the prominent oncogenes HMGA1 and TACSTD2, established a yet unknown link between RRM2 and PLK1 and identified RPS2 and NOL5A as promising potential therapeutic targets in CRC.
|
20473941 |
2011 |
|
Colorectal Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
Examination of clinical CRC specimens demonstrated that both RRM2 and E2F1 were elevated in most cancer tissues compared to the paired normal tissues.
|
26093293 |
2015 |
|
Colorectal Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
To investigate further the relevance of RRM2 and CRCs (colorectal cancers), we correlated the expression of RRM2 with the clinical outcome of CRCs.
|
23113760 |
2013 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
In conclusion, FAM138B‑hsa‑miR‑30c‑CCNE2/RRM2 and the SSTR5‑AS1‑hsa‑miR‑15b‑5p‑CA2 ceRNA axes may be important mechanisms for HBV‑related HCC.
|
31638225 |
2019 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Thus, ADR-RRM2-TLPD represents a potential strategy for combined therapy of HCC overexpressing EGFR.
|
24060417 |
2013 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
RRM2 phosphoprotein interaction module construction in HCC can be a new route for studying the pathogenesis of HCC.
|
20798514 |
2010 |
|
Liver carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
We have previously demonstrated that suppression of RRM2 expression could substantially inhibit hepatocellular carcinoma cell proliferation and migration.
|
29710515 |
2018 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Furthermore, cell cycle and p53 signaling pathways may play vital mediatory roles; CDK1 may play crucial roles in HCC transformed from cirrhosis via cell cycle and p53 signaling pathways, and RRM2 might be involved in HCC transformed from cirrhosis via the p53 signaling pathway.
|
28640074 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Ribonucleotide reductase subunit M1 and RRM2 mRNA expression in lung adenocarcinoma tumours is associated with clinical outcome to docetaxel/gemcitabine.
|
18414411 |
2008 |
|
Malignant neoplasm of urinary bladder
|
0.220 |
AlteredExpression
|
disease |
BEFREE |
Recently, high levels of RRM2 expression were reported to correlate with poor survival outcomes in patients with colorectal and bladder cancer.
|
25695839 |
2015 |
|
Malignant neoplasm of urinary bladder
|
0.220 |
AlteredExpression
|
disease |
BEFREE |
We have shown frequent overexpression of RRM2 protein and its possible role in bladder cancer.
|
21166702 |
2010 |
|
Bladder Neoplasm
|
0.220 |
AlteredExpression
|
disease |
BEFREE |
Recently, high levels of RRM2 expression were reported to correlate with poor survival outcomes in patients with colorectal and bladder cancer.
|
25695839 |
2015 |
|
Bladder Neoplasm
|
0.220 |
AlteredExpression
|
disease |
BEFREE |
We have shown frequent overexpression of RRM2 protein and its possible role in bladder cancer.
|
21166702 |
2010 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The genes MTIM and RRM2 appeared in nine and TOP2A in eight lists of significantly altered genes in cancer.
|
21165954 |
2011 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The RRM2 expression in cancer tissues was higher than that in high-grade dysplasia, low-grade dysplasia or normal cervical tissues.
|
24637958 |
2014 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy.
|
23719266 |
2013 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Importantly, a second RRM domain (RRM2) of RBM10 recognizes a C-rich sequence, which explains its known interaction with the intronic 3΄ site of NUMB exon 9 contributing to regulation of the Notch pathway in cancer.
|
28379442 |
2017 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
As the ribonucleotide reductase small subunit, the high expression of ribonucleotide reductase small subunit M2 (RRM2) induces cancer and contributes to tumor growth and invasion.
|
26093293 |
2015 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Importantly, RRM2 functions like a tumor driver in most types of cancer but little is known about the regulatory mechanism of RRM2 in cancer development.
|
27801665 |
2016 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In our previous study, ribonucleotide reductase M2 (RRM2) was identified as a cancer-related gene commonly overexpressed in human oral squamous cell carcinoma (OSCC) cell lines.
|
25738429 |
2015 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The overexpression of RRM2 [RR (ribonucleotide reductase) small subunit M2] dramatically enhances the ability of the cancer cell to proliferate and to invade.
|
23113760 |
2013 |